Exalenz Bioscience , developer of advanced diagnostic systems that use the patient’s breath to assess gastrointestinal and liver conditions, announced today that the company was granted its first patent for a liver application of its technology. The patent was granted by the United States Patent and Trademark Office. Patent number 8,512,258 was granted to Exalenz for the BreathID Platform Technology’s method of evaluating the liver condition of a patient.
Exalenz’s breath test liver application is designed to evaluate the liver condition of a patient by computing and comparing breath test parameters, before and after ingestion of a test substrate in real-time, while collecting a continuous flow of the patient’s breath, as described in the patent announced today. The technology has multiple diagnostic applications. For example: Exalenz conducted an extensive market survey which showed that there is a clear need for a simple, non-invasive test for detecting the onset of Clinically Significant Portal Hypertension (CSPH), an increase in blood pressure in the veins of the portal system caused by obstruction in the liver. Chronic high blood pressure is prevalent in advanced stages of chronic liver disease and affects liver function. Today, direct measurement of portal pressure is invasive, costly, inconvenient, and requires highly-skilled and experienced physicians to perform the procedure accurately.
“We are enthusiastic about today’s patent. Exalenz intends to develop an impressive product pipeline based on the BreathID Technology Platform. Today’s achievement marks the latest progress in this ongoing initiative,” said Exalenz CEO Mr. Lawrence Cohen. “It has been a busy summer. In July, we launched the BreathID Hp for the detection and management of the H. pylori bacteria. We also established a new direct US sales team purposed to better service our valued customers. We are looking forward to continuing the momentum and to more exciting developments in the fall.”
